OXFORDSHIRE TRAFFIC LIGHT CLASSIFICATION FOR PRESCRIBING RESPONSIBILITY Updated following APCO September
2015 & OCCG Clinical Ratification Group October 2015
Key
Red List – Specialist Prescribing Only (pink highlight indicates funded by specialised commisioning)
Yellow (Near Patient Testing LES) – Transfer of prescribing to primary care in line with Shared Care Protocol.
Monitoring in Primary Care
Yellow - Transfer of prescribing to primary care. Monitoring in Secondary Care
Yellow Continuation List– Appropriate for Continuation in Primary Care following specialist recommendation
Brown – Prescribe only in restricted circumstances
Black – Not recommended for use
Alphabetical Index of all drugs traffic lighted to date
DRUG
4 ULCER CARE - MAGNETIC DRESSING APCO March 06
ABACAVIR APCO Sept 2005
ABATACEPT after the failure of a TNF inhibitor APCO Sept 2010
ABATACEPT for the treatment of rheumatoid arthritis after the failure of conventional disease modifying drugs
APCO Sept 11
ABIRATERONE for castration resistant metastatic prostate cancer previously treated with a docetaxel-containing
regimen APCO July 12
ABNOBAVISCUM (MISTLETOE EXTRACT) for malignant melanoma
ACETYLCYSTEINE
ACETYLCYSTEINE for paracetamol overdose
ACITRETIN March 2007
ACRIFLAVINE CREAM
ADALIMUMAB
ADALIMUMAB for the treatment of moderate to severe ulcerative colitis
ADEFOVIR for Hepatitis B
ADEFOVIR for HIV APCO Sept 2005
AFLIBERCEPT SOLUTION for injection for the treatment of wet AMD APCO Sep 13
AFLIBERCEPT for diabetic macular oedema APCO Sept 15
AGOMELATINE APCO Sep 11
ALEMTUZUMAB for treating relapsing-remitting multiple sclerosis
ALFENTANIL APCO Mar 12
ALFUZOSIN APCO July 06
ALISKIREN for hypertension APCO June 07
ALITRETINOIN for the treatment of severe chronic hand eczema APCO Sep 09
ALOGLIPTIN APCO May 2014
ALPROSTADIL for penile rehabilitation after radical prostatectomy
ALPROSTADIL cream (Vitaros®) for erectile dysfunction APCO July 15
AMANTADINE for the treatment or prophylaxis of influenza
AMIFAMPRIDINE (FIRDAPSE®) APCO Jan 11
AMIODARONE APCO May 11
AMISULPIRIDE for Behavioural and Psychiatric symptoms of dementia APCO May 11
ANAGRELIDE APCO Nov 07
ANAKINRA APCO May 08
ANAL IRRIGATION
ANASTRAZOLE APCO May 07
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (anti-VEGF) as an adjuct to vitrectomy for proliferative
diabetic retinopathy- bevacizumab (Avastin) only. APCO Nov 10
APIXABAN for AF May 2014
APIXABAN for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
APCO July 2013
TRAFFIC
LIGHT
Black
Red
Red
Black
Red
Black
Black
Red
Red
Black
Red
Black
Red
Black
Red
Red
Black
Red
Yellow SCP
Black
Black
Red
Brown
Black
Black
Black
Black
Yellow SCP
Brown
Red
Red
Yellow
Yellow
Continuation
Red
Brown
Rationale
Priorities Forum Statement
All HIV drugs should be prescribed by specialist centres only
Specialist prescribing only
Not recommended for prescribing
In line with NICE TA 259
Insufficient evidence
Not recommended for prescribing
In line with NICE TA195
Specialist prescribing only
No evidence to support use
Specialist prescribing only in line with local commissioning arrangements and NICE TAG 187,
TA195 & TA199
In line with NICE TA 262
Shared Care protocol withdrawn - hospital precribing only
All HIV drugs should be prescribed by specialist centres only
In line with NICE 294
In line with NICE TA 346
In line with NICE TA 231
NICE TA Specialised Commissioning
Restricted prescribing in line with shared care protocol
Not accepted on to OUHT formulary due to lack of evidence
Lack of comparative clinical and cost effectiveness data and local guidance. Not on OUHT
formulary
In line with NICE TAG 177
First choice of gliptin
In line with lavender statement 233
To be reviewed as part of lavender statement review via TVPC
Not recommended
Not on OUH Formulary
In line with shared care protocol.
Short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of
Dementia: Prescribing Guidance (2nd line IF antipsychotic required - off license use)
Specialist prescribing only until an appropriate Shared Care Protocol agreed
Specialist prescribing only in line with local commissioning arrangements
In line with TVPC recommendation
Only prescribe according to Oxfordshire Guidelines
In line with MOBBB Priorities Forum
In line with NICE TA 275 and local guidelines
Yellow
In line with NICE TA 341. First three months tx to be provided by OUH for new DVT/PE.
APIXABAN for preventing VTE after total hip or knee replacement in adults
APCO Mar 13
APOMORPHINE APCO May 10
AQUADEKS APCO Mar 12
ARIPIPRAZOLE APCO Sep 04
ARIPIPRAZOLE for Behavioural and Psychiatric symptoms of dementia APCO Sep 11
ARIPIPRAZOLE for the treatment of schizophrenia in people aged 15 to 17 years APCO May 11
ARIPIPRAZOLE for treating moderate to severe manic episodes in adolescents with bipolar 1 disorder APCO Sep
13
Red
Yellow
Brown
Yellow
Continuation
Brown
Yellow
Continuation
In line with NICE TA 245
In line with the APCO approved shared care protocol
Restricted prescribing for children with cystic fibrosis.
Oxford Health (Mental Health) consultants only
Short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of
Dementia: Prescribing Guidance (2nd line IF antipsychotic required - off license use)
In line with TA 213
Red
Yellow
Continuation
Black
Red
Yellow SCP
Yellow
In line with TA292
In line with TA 218
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Shared care protocol
Shared Care Protocol
No evidence to support its place in therapy over other cheaper sartans.
AZITHROMYCIN for cystic fibrosis APCO March 2003
BACLOFEN INTRATHECAL for spasticity APCO Nov 2007
BALSALAZIDE APCO June 07
BARBITURATES APCO July 11
BARBITURATES for addiction APCO July 11
BARBITURATES for epilepsy APCO July 11
Bard Catheter Trays APCO Jan 14
BASILIXIMAB APCO Sept 05
BD Autoshield needles APCO Nov 14
BENDAMUSTINE for relapsed or refractory non-Hodgkin’s lymphoma APCO Sept 2010
BENDAMUSTINE for the treatment of chronic lymphocytic leukaemia APCO May 2011
Red
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Black
Yellow
Continuation
Red
Black
Red
Black
Yellow
Black
Red
Black
Red
Red
BENZODIAZEPINES - should not be used for GAD except as a short-term measure during crises APCO May 11
BETA-INTERFERON
BETAMETHASONE 2.250mg medicated plaster (BETESIL®) APCO Mar 10
Brown
Red
Black
In line with CG 113
Treatment from OUHT providing patient fits certain criteria
Lack of comparative clinical and cost effectiveness data
ARIPIPRAZOLE ORO-DISPERSIBLE APCO Nov 06
ARTHROTEC APCO Jan 14
ATAZANAVIR APCO Sept 2005
ATOMOXETINE APCO Nov 10
AURANOFIN
AZACITIDINE for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute
myeloid leukaemia APCO May 2011
AZATHIOPRINE for inflammatory arthritis APCO Nov 2010
AZATHIOPRINE for inflammatory bowel disease APCO May 11
AZATHIOPRINE in idiopathic pulmonary fibrosis APCO Nov 10
AZATHIOPRINE for liver transplant and autoimmune liver disease APCO Sep 11
AZATHIOPRINE in children and adolescents (Rheumatology) APCO July 11
AZATHIOPRINE in dermatology APCO May 12
AZATHIOPRINE in sarcoidosis APCO Nov 11
AZILSARTAN APCO Sep 12
BEVACIZUMAB (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma APCO Sept 2009
BEVACIZUMAB for diabetic macular oedema APCO Jan 12
BEVACIZUMAB for macular oedema caused by retinal vein occlusion APCO Jan 12
BEVACIZUMAB for metastatic colorectal cancer after first line chemotherapy APCO Jan 12
BEVACIZUMAB for neo-vascularisation in non wet-AMD conditions and glaucoma prior to laser treatment. APCO
Jan 10
Black
Black
Black
Black
Red
BEVACIZUMAB in combination with a taxane for the first-line treatment of metastatic breast cancer APCO May 11 Black
BEVACIZUMAB in combination with capecitabine for the first line treatment of metastatic breast cancer APCO
Black
Sept 2012
BEVACIZUMAB in combination with gemcitabine and carboplatin for treating people with the first recurrence of
Black
platinum-sensitive advanced ovarian cancer
Following recommendation
Not in line with policy
All HIV drugs should be prescribed by specialist centres only
Oxford Health - Mental Health consultants only. Shared Care Protocol
Not currently used in Oxfordshire
Detailed information will be provided by the consultant
Specialist prescribing only
Not currently recommended for prescribing as not on the OUHT formulary
Secondary care prescribing only
for the treatment of addiction
Phenobarbital for epilepsy
More expensive than components
Specialist initiation and prescribing only
No GP prescribing, to be supplied by OH
In line with MOBBB Priorities Forum and with NICE TA206
In line with TA 216
In line with NICE TAG 178
In line with MOBBB Commissioning Policy Statement 211
In line with MOBBB Commissioning Policy Statement 212
In line with NICE TA 242
In line with Priorities Forum
In line with TA 214
In line with NICE TA 263
In line with NICE TA 285
BEVACIZUMAB in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the
treatment of metastatic colorectal cancer APCO Jan 11
BEVACIZUMAB in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
APCO July 13
BEXAROTENE APCO Nov 10
BIOLOGICAL DISEASE MODIFYING DRUGS in rheumatoid arthritis (anti-TNF drugs) APCO July 11
BIOLOGICAL DISEASE MODIFYING DRUGS in rheumatoid arthritis (anti-TNF drugs) APCO July 11
BIOTIN for Paediatric Neurologists APCO Sep 13
BLEOMYCIN APCO July 08
BOCEPREVIR APCO May 12
BORTEZOMIB APCO July 2008
BORTEZOMIB and thalidomide for the first-line treatment of multiple myeloma APCO Sept 11
BORTEZOMIB for dialysis prevention in untreated myeloma
BOSENTAN
BOTULINUM TOXIN for anal fissure/bladder over activity
BOTULINUM TOXIN for axillary hyperhidrosis
BOTULINUM TOXIN Type A for chronic headache(excluding chronic migraine) APCO July 12
BOTULINUM TOXIN Type A for chronic migraine APCO July 12
BRIGHT EYES APCO Sep 12
BRIMONIDINE Gel for rosacea APCO July 14
BROMFENAC EYE DROPS APCO Nov 13
BUPRENORPHINE and NALOXONE (SUBOXONE®) APCO July 10
BUPRENORPHINE PATCHES APCO July 15
BUPRENORPHINE s/l tablets for the treatment of addiction APCO July 11
BUPROPION for smoking cessation APCO Nov 07
BUSERELIN for Central precocious puberty (CPP) APCO May 11
BUSULFAN APCO July 2008
CABAZITAXEL for hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing
regimen APCO July 12
CALC FOLINATE APCO July 08
CALC LEVOFOLINATE APCO Jul 08
CALCITONIN for men with primary and scondary prevention of fractures APCO Nov 12
CANAGLIFLOZIN APCO July 14
CANAKINUMAB for the treatment of Gout APCO May 13
CANGRELOR for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or
awaiting surgery requiring interruption of anti‑platelet therapy APCO Sept 15
CANNABINOIDS (MEDICAL)
CAPECITABINE APCO July 08
CAPREOMYCIN APCO July 2012
CAPSAICIN patch (QUETENZA®) APCO Sep 10
CARBOPLATIN APCO July 08
CARMUSTINE APCO July 08
CARMUSTINE IMPLANTS APCO Sept 10
CARNITINE APCO Jan 04
CAVILON APCO Mar 14
CEFUROXIME APCO Sep 12
CERAZETTE® APCO Jan 11
CERTOLIZUMAB PEGOL for rheumatoid arthritis APCO Mar 10
CETUXIMAB (for squamous cell carcinoma) APCO July 09
CETUXIMAB for metastatic colorectal cancer APCO Sept 11
CETUXIMAB for metastatic colorectal cancer after first line chemotherapy APCO Mar 12
CETUXIMAB for the first-line treatment of metastatic colorectal cancer APCO sept 09
Black
In line with TA 212
Black
Black
Red
Black
Red
Red
Red
Red
Red
Black
Red
Red
Black
Black
Red
Black
Black
Red
Black
In line with NICE TA 284
In line with MOBBB Priorities Forum
indications within NICE in line with MOBB priorities statement 201
indications outside NICE in line with MOBB priorities statement 201
unlicensed
Specialist prescribing only
In line with NICE TA 253
Specialist prescribing only. Low priority for prescribing in Oxfordshire
In line with TA 228
In line with MOBBB Priorities Forum
Should only be prescribed by one of four specialist centres
Prescribed by specialists only for anal fissure/bladder over activity
Low priority for prescribing for axillary hyperhidrosis
In line with MOBBB Commissioning Policy Statement 224.
In line with NICE TA 260
No evidence to support its place in therapy.
Lack of evidence, costly, awaiting TVPC
Full supply to be provided by OUHT
In line with APCO approved Guidance for Substance Misuse
Yellow
On recommendation by pain specialist only. For patients with stable pain who have swallowing
difficulties and cannot tolerate other options. Not to be used for any other patient group.
Under shared care drug misuse LES only
For consideration second line after NRT in order to be consistent with guidance for
varenicline
Shared Care Protocol
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Brown
Brown
Yellow
Red
black
Red
Red
black
Brown
black
Black
Black
Red
Red
Black
Red
Red
Red
Red
Black
Brown
Brown
Red
Black
Black
Black
Red
In line with NICE TA 255
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Specialist prescribing only
in Line with lavender statement 232
In line with NICE TA 315
In line with NICE terminated appraisal
In line with NICE TA 351
In line with Priorities Forum
In line with NPSA Rapid Alert on Oral Anticancer Medicines and NICE TA 191
Specialist prescribing only
lack of clinical and cost effectiveness data
Specialist prescribing only
Secondary care prescribing only.
Secondary care prescribing only. In line with lavender statement 83a, NPSA Rapid Alert on Oral
Anticancer Medicines and TA 191
Renal physicians only
Replaced by Medi Derma S as less expensive and similar efficacy
In line with Oxfordshire paediatric antimicrobial guidelines- only for cat or dog bites if child is
allergic to penicillin.
Restricted use for use in women in whom a POP is indicated but who find the strict 3 hour regimen
of standard POPs difficult to adhere to.
In line with NICE TA186
Not recommended as per NICE guidance.
In line with Policy Statement 208/MOBBB Statement 52
In line with NICE TA 242
In line with NICE TAG 176
CHLORAMBUCIL APCO July 08
CHLORMETHINE HYDROCHLORIDE APCO July 08
CHOLESTAGEL APCO Sept 08
CICLOSPORIN for inflammatory arthritis APCO Nov 10
CICLOSPORIN for inflammatory bowel APCO May 11
CICLOSPORIN for psoriasis APCO May 11
CICLOSPORIN for severe inflammatory skin disease APCO May 11
CILOSTAZOL APCO July 11
CINACALCET APCO Jan 05
CISPLATIN APCO July 08
CLADRIBINE APCO July 08
CLINDAMYCIN - oral APCO July 2010
CLINDAMYCIN for infective endocarditis APCO Nov 09
CLOFARABINE APCO July 08
CLOPIDOGREL with DYPYRIDAMOLE MR for the prevention of occlusive vascular events APCO Jan 11
CLOZAPINE APCO Jan 11
COLECALCIFEROL 800IU (Fultium-D3®) APCO Jan 12
COLECALCIFEROL CAPSULES (10,000IU and 50,000IU) APCO Sep 11
COLECALCIFEROL TABLETS (10,000IU and 50,000IU) APCO Sep 11
COLESEVELAM
COLESEVELAM for bile acid malabsorption APCO Nov 13
COLISTIMETHATE SODIUM (Nebulised COLOMYCIN) APCO Nov 13
COLISTIMETHATE SODIUM (PROMIXIN®) APCO Mar 10
COMPRESSION HOSIERY for DVT and early use in oedema to prevent lymphodema APCO Sept 15
CO-PROXAMOL APCO May 05
CRISANTASPASE APCO July 08
CRIZOTINIB for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase
fusion gene APCO Nov 13
CUTIMED SORBACT APCO Sept 14
CYCLOPHOSPHAMIDE APCO July 08
CYSTISTAT® (PURIFIED HYALURONIC ACID) APCO Jan 11
CYTARABINE APCO July 08
DABIGATRAN APCO May 2014
DACARBAZINE APCO July 08
DACTINOMYCIN APCO July 08
DALTEPARIN for DVT & long haul flight prophylaxis APCO Jan 15
DALTEPARIN for perioperative anticoagulation, extended thromboprophylaxis & post-partum, intermediate risk
pregnancy and Trauma APCO Jan 15
DALTEPARIN for sub-therapeutic INRs, DVT in patients with cancer, IV drug users & first doses in high risk
pregnancy APCO Jan 15
DAPAGLIFLOZIN July 13
DAPOXETINE APCO Mar 2014
DAPTOMYCIN APCO Jan 11
DARBEPOETIN APCO Nov 05
DARIFENACIN for overactive bladder syndrome APCO May 11
DASATINIB APCO July 2008
DASATINIB for CML resistant to standard dose imatinib APCO Mar 2012
DASATINIB for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance
70) APCO May 2012
DAUNORUBICIN APCO july 2008
DEFERASIROX APCO Nov 06
Red
Red
Black
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Black
Red
Red
Red
Yellow
continuation
Brown
Red
Yellow
Yellow (NPT)
Brown
Red
Black
Yellow
Black
Red
Black
Black
Black
Red
Black
Black
Red
Black
Red
Brown
Red
Red
Brown
Red
Yellow
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Specialist prescribing only
Not appropriate for prescribing
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
in line with NICE TA223
In line with NICE TA 117
Secondary care prescribing only.
Specialist prescribing only
Following recommendation
Second line prophylaxis (penicillin allergy) for infective endocarditis.
Specialist prescribing only
In line with TA 210
Shared Care Protocol
For osteoporosis patients with a high calcium intake. Similar costs to standard calcium and vitamin
D preparations
Hospital Prescribing only
Not on OUH formulary. No prescribing in primary care
In line with SCP
NICE evidence summary
Funding by NHS England Specialist Commissioning
Not on OUH formulary. Rejected by MAC.
No evidence of benefit. Can be used for prevention of recurrence of leg ulcers and for 3 months
for varicose veins
No longer suitable for prescribing
Specialist prescribing only
In line with NICE TA 296
Insufficient evidence
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Limited clinical benefit, and any benefit demonstrated in published studies appears to be shortterm
Specialist prescribing only
In line with NICE TA 249 and local guidelines (to be updated)
Specialist prescribing only
Specialist prescribing only
In line with DVT LES: One off, initial dose only, if outside of DVT clinic hours. Flight prophylaxis
rarely required, see Oxfordshire dalteparin guidelines
Specialist prescribing only. In line with Dalteparin – Guidelines for Prescribing in Primary Care
Brown
In line with Dalteparin – Guidelines for Prescribing in Primary Care
In line with NICE TA288
Black
Commissioning pathway under review
Red
Red
Black
Red
Black
Black
Red
Red
For use at the OUH (NOC) only on advice of ID or Microbiology Consultants in specific situations
All prescribing (and funding) transferred to Renal Unit in September 2005. For secondary care
prescribing only
Not recommended
In line with NPSA Rapid Alert on Oral Anticancer Medicines
In line with NICE TA 241
In line with NICE TA 251
Specialist prescribing only
Specialist prescribing only
DEFERIPRONE APCO Nov 06
DEGARELIX for tumour flare prevention in prostate cancer APCO May 11
DEHYDROEPIANDOSTERONE SULPHATE (DHEAS) APCO July 04
DENOSUMAB for the primary and secondary prevention of osteoporotic fractures APCO Aug 14
DENOSUMAB for the prevention of skeletal-related events in adults with bone metastases
DENOSUMAB for the prevention of skeletal-related events in adults with bone metastases - prostate cancer
related
DENOSUMAB for therapy-induced bone loss in non-metastatic prostate cancer APCO Sep 10
DERMASILK GARMENTS APCO July 09
DESFERRIOXAMINE APCO Nov 06
DESMOPRESSIN NASAL SPRAY (OCTIM®) APCO Sep 05
DESSICATED THYROID PRODUCTS (eg ARMOUR THYROID) APCO Nov 12
DEXAMETHASONE intravitreal implant for treating diabetic macular oedema APCO Sept 15
DEXAMFETAMINE APCO jul 2011
DEXRAZOXANE APCO jul 08
DEXTROMORAMIDE for the treatment of addiction APCO July 11
DIAMORPHINE - 500mg APCO July 11
DIAMORPHINE in Substance Misuse APCO July 11
DIAMORPHINE reefers APCO July 11
DIDANOSINE APCO Sept 2005
DILTIAZEM 2% OINTMENT APCO Nov 06
DIPIPANONE (DICONAL®) APCO July 11
DISODIUM FOLINATE APCO jul 2008
DOCETAXEL APCO Jul 2008
DOMPERIDONE APCO jul 2014
DORNASE ALPA in children with cistic fibrosis
DOSULEPIN APCO May 05
DOXAZOSIN for BPH APCO Mar 04
DOXAZOSIN for hypertension APCO Mar 04
DOXAZOSIN MR APCO Mar 04
DOXORUBICIN HYDROCHLORIDE APCO Jul 08
DRONEDARONE APCO Jan 11
DROTRECOGIN ALFA (ACTIVATED)
DULOXETINE for depression APCO Mar 05
DULOXETINE for neuropathic pain APCO May 13
DULOXETINE for stress incontinence APCO Jul 06
DUODOPA INTESTINAL GEL
DuoResp Spiromax
DURAPHAT® HIGH FLOURIDE TOOTHPASTE APCO Jan 11
DUTASTERIDE APCO Sep 11
DYMISTA ® APCO May 13
EFALIZUMAB APCO Mar 09
EFAVIRENZ APCO sept 2005
EFLORNITHINE sept 2005
ELMIRON® (PENTOSAN POLYSULFATE SODIUM) APCO july 2010
ELTROMBOPAG for chronic immune idiopathic thrombocytopenic purpura APCO Nov 2010
EMPAGLIFLOZIN
ELTROMBOPAG for the treatment of chronic immune or idiopathic thrombocytopenic purpura APCO Nov 2010
EMTRICITABINE APCO sept 2005
ENALAPRIL APCO Nov 05
ENFUVIRTIDE APCO sept 05
ENSURE SHAKE APCO NOV 14
Red
Black
Black
Brown
Red
Black
Black
Black
Red
Red
Black
Red
Yellow
Red
Black
Red
Red
Black
Red
Black
Black
Red
Red
Brown
Red
Brown
Black
Brown
Black
Red
Yellow (NPT)
Red
Yellow
Continuation
Brown
Yellow
Continuation
Black
Black
Black
Black
Black
Black
Red
Black
Black
Red
Yellow
Black
Red
Brown
Red
Brown
Specialist prescribing only
Not recommended
In line with NICE TA204 and local guidelines
In line with NICE TA 265
In line with NICE TA 265
In line with NICE TA194
Lack of evidence or cost-effectiveness data available.
Specialist prescribing only
Specialist prescribing only
Not recommended for rxing as no eveidence to support use over licensed alternatives
In line with NICE TA 349
In line with ADHD shared care protocol
Specialist prescribing only
In line with National Clinical Assessment Service (NCAS guidance)
Specialist prescribing only
Specialist prescribing only
In line with National Clinical Assessment Service (NCAS guidance)
All HIV drugs should be prescribed by specialist centres only
Not accepted on to OUHT formulary
In line with National Clinical Assessment Service (NCAS guidance)
Specialist prescribing only
Specialist prescribing only
Short term use for nausea and vomiting only in line with MHRA
Specialist prescribing only
New patients should not be initiated in general practice
Not recommended
In line with NICE guidance for hypertension
Not recommended - use standard release doxazosin
Specialist prescribing only
In line with APCO Shared Care Protocol
To only be prescribed within an intensive care setting
Prescribe following recommendation from Oxford Health (Mental Health) only
Pain guidelines currently under review
Prescribe following recommendation from specialists only
In line with priorities statement
Non Formulary in line with COPD guidelines
Included on dental formulary therefore dentists should prescribe where appropriate rather than
refer to the GP.
No evidence of advantage over finasteride or that patients failing on finasteride will benefit from
dutasteride
No evdience of cost efficacy and not in line with current guidelines (use of intranasal corticosteroid
with oral antihistamine recommended)
Marketing authorisation suspended
All HIV drugs should be prescribed by specialist centres only
Low priority
Not on OUH formulary , unlicensed & no cost- efficacy data
In line with NICE TA 293
In line with NICE 336
In line with NICE TA205
All HIV drugs should be prescribed by specialist centres only
No longer recommended for initiation in new patients
All HIV drugs should be prescribed by specialist centres only
Aymes first line
ENOXAPARIN APCO Sep 08
ENTACAPONE
ENTECAVIR APCO Sep 08
EPIPEN for home IV iron haemodialysis patients APCO Jan 14
EPIRUBICIN HYDROCHLORIDE
EPLERENONE
EPLERENONE APCO Nov 13
ERDOSTEINE
ERECTILE DYSFUNCTION DRUGS
ERIBULIN for the treatment of locally advanced or metastatic breast cancer APCO May 12
ERLOTINIB
ERLOTINIB for 2nd line treatment of non-small cell lung cancer APCO Sep 12
ERLOTINIB for the first-line treatment of locally advanced or metastatic EGFR-TK mutation_positive none-small
cell lung APCO Sep 12
ERLOTINIB monotherapy for the maintenance treatment of non-small cell lung cancer APCO Sep 11
Black
Yellow
Continuation
Red
Red
Red
Brown
Yellow
Continuation
Brown
Brown
Black
Red
Black
Black
Black
Red
ERYTHROPOIETIN for renal disease APCO Nov 05
ESCITALOPRAM APCO Sep 02
ESOMEPRAZOLE 20mg
ESOMEPRAZOLE 40mg
ESOMEPRAZOLE GRANULES APCO July 13
ESTRAMUSTINE PHOSPHATE
ETANERCEPT APCO Sep 10
ETOGLUCID
ETOPOSIDE
EVEROLIMUS (with an aromatase inhibitor) for HER2 negative, oestrogen receptor positive, locally advanced or
metastatic breast cancer
EVEROLIMUS for second-line treatment of advanced renal cell carcinoma APCO May 11
EVEROLIMUS for preventing organ rejection in liver transplantation APCO Sept 15
EXEMESTANE APCO May 07
EXENATIDE APCO July 13
EXENATIDE prolonged release suspension APCO May 12
EZETIMIBE APCO Jan 15
FEBUXOSTAT APCO Sep 08 link
FENTANYL BUCCAL TABLETS (EFFENTORA®) APCO Nov 08
FENTANYL IONTOPHORETIC TRANSDERMAL SYSTEM (IONYSIS®) APCO May 08
FENTANYL LOZENGES (ACTIQ®) APCO Nov 08
FESOTERODINE APCO May 11
Fexofenadine Mar 14
FIDAXOMICIN for use in C Diff APCO Sep 13
FILGRASTIM (RECOMBINANT HUMAN GRANULOCYRE-COLONY STIMULATING FACTOR) APCO Sep 07
FINGOLIMOD for the treatment of highly active relapsing-remitting multiple sclerosis APCO May 12
FIRDAPSE APCO Sep 12
FLAMINAL APCO Mar 08
FLOXURIDINE
FLUDARABINE PHOSPHATE
FLUNARIZINE for migraine prophylaxis APCO July 15
Black
Black
Brown
Brown
Red
Red
Red
Red
Black
Black
Black
Yellow
Continuation
Brown
Brown
Brown
Brown
Black
Red
Black
Yellow
Continuation
Brown
Red
Red
Red
Black
Black
Red
Red
Red
Not appropriate for prescribing
Must be initiated and monitored by specialists in secondary care with expertise in management of
patients with Parkinson's disease
In line with NICE TA 153
Hospital supply iron with epipen
Specialist prescribing only
Prescribe in restricted circumstances
Second line for patients that cannot tolerate spironolactone
APCO March 2007
In line with DH and local guidance
In line with NICE TA 250
In line with NPSA Rapid Alert on Oral Anticancer Medicines and NICE TA 258
Until erlotinib is equal in cost to docetaxal in line with NICE TA 162
In line with NICE TA 258
In line with NICE TA 227
All prescribing (and funding) transferred to Renal Unit in September 2005. For secondary care
prescribing only. Shared Care protocol available for monitoring requirements IF these cannot be
undertaken within secondary care.
No significant advantage over citalopram
Not on OUHT formulary. Omeprazole and lansoprazole capsules are current first line choices.
Omeprazole 40mg is equivalent to Esomeprazole 20mg in terms of bioavailability.
Restricted for patients with significant symptoms requiring very high dose PPI treatment.
Restricted for use in enteral tube patients where a small tube is being used or where blockage
problems have occurred with lansop fast tabs/Omep MUPs
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Specialist prescribing only in line with local commissioning arrangements & NICE TA195 & TA199
Specialist prescribing only
In line with NPSA Rapid Alert on Oral Anticancer Medicines
In line with NICE TA 295
In line with TA 219
In line with NICE TA 348
In line with local guidelines
In line with local GLP1 guidelines
In line with agreed Exenatide Prescribing Guidelines
In line with local guidelines
Restricted prescribing in line with NICE TAG 164.
Limited information available re place in therapy. Currently no request to use by Palliative Care
Team.
Specialist prescribing only
Limited information available re place in therapy. Currently no request to use by Palliative Care
Team.
In line with PCT Prescribing guidance
No advantage over other antihistamines, disadvantage of not available OTC
Specialist prescribing within secondary care
Specialist prescribing only
Specialist prescribing only in line with NICE TA 254
In line with MOBB statement.
Not recommended
Specialist prescribing only
In line with NPSA Rapid Alert on Oral Anticancer Medicines
To be prescribed by specialist, unlicensed and named patient only
FLUOCINOLONE ACETONIDE for diabetic macular oedema
Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an
inadequate response to other therapy APCO Mar 13
FLUOROURACIL (ORAL)
Black
Black
Red
Brown
FLUTICASONE FUROATE nasal spray (Avamys®)
FLUTICASONE NASULES
FOSAMPRENAVIR
FOSFOMYCIN APCO Sep 13
FULVESTRANT APCO Nov 07
FULVESTRANT for the treatment of locally advanced or metastatic breast cancer APCO Jan 12
FUMADERM APCO Mar 04
GALANTAMINE for the treatment of Alzheimers Disease APCO Sep 11
GARMENTS INCLUDING SKINNIES AND DREAMSILK apco March 2015
GALANTAMINE for the treatment of dementia associated with Parkinson’s disease or Lewy Bodies
GAMOLENIC ACID
GARDASIL Human papillomavirus (HPV) vaccine
GEFITINIB for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer
GEMCITABINE
GLICLAZIDE MR APCO Sep 11
GLUCOSAMINE
GLUTEN FREE FOODS APCO Sep 12
GLUTEN FREE FOODS for treatment of autism APCO Jan 03
GLYCOPYRONIUM BROMIDE APCO July 12
GLYCOPYRRONIUM BROMIDE (Seebri Breezhaler®) APCO Jan 13
GLYCOPYRRONIUM for hypersalivation for mental health patients APCO Sep 13
GLYCOPYRRONIUM INHALER for COPD APCO Nov 13
GLYCOPYRRONUIM for hypersalivation for neuro patients APCO Sep 13
GLYCOPYRRONUIUM for hyperhydrosis
GOLD (SODIUM AUROTHIOMALATE) for inflammatory arthritis APCO Nov 10
GOLIMUMAB APCO Sep 11
GOSERELIN for Central precocious puberty (CPP) APCO May 11
GRANISETRON APCO May 10
GRAZAX® - ORAL GRASS POLLEN VACCINE APCO May 07
GROWTH HORMONE for “small for gestational age” (SGA) children APCO July 10
GROWTH HORMONE IN ADULTS APCO May 11
GROWTH HORMONE IN CHILDREN APCO July 10
GTN 0.4% ointment APCO June 07
HAELAN TAPE for cracked heels APCO May 13
HAELAN TAPE for eczema APCO May 13
HAELAN TAPE for keloid scars APCO July 13
HEAD LICE DEVICES as listed in Drug Tariff IXA APCO July 08
Brown
Red
Red
Black
Black
Red
Yellow
Black
Yellow
Continuation
Black
Black
Red
Red
Black
Black
Brown
Black
Brown
Black
Red
Black
Yellow
Black
Yellow (NPT)
Red
Black
Black
Black
Yellow
Yellow (NPT)
Yellow
Brown
Black
Black
Black
Black
Black
HEEL BALMS (DERMATONICS® and FLEXITOL®) APCO Sep 11
HOME PARENTERAL NUTRITION APCO Sep 03
HYALURONIC ACID APCO Mar 09
HYDROCOTISONE MR (Plenadren®) APCO Jan 13
HYDROXYCARBAMIDE (HYDROXYUREA) APCO July 11
HYDROXYCHLOROQUINE for inflammatory arthritis APCO Nov 10
HYDROXYCHLOROQUINE in children and adolescents (Rheumatology) APCO Jul 11
Yellow
Red
Black
Yellow (NPT)
Yellow
Yellow
Specialised commissioning decision
Not recommended in line with NICE TA 271
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Restricted prescribing 3rd line if fluticasone is being considered. No comparative studies with
beclomethasone (1st line) or momentasone (2nd line) which are more cost effective preparations
Restricted prescribing for patients with hypo osmia, Aspirin Sensitive Asthma & after 6 week trial of
steroid nasal spray for nasal polyps.
All HIV drugs should be prescribed by specialist centres only
Unlicensed
Not recommended
In line with NICE TA 239
For prescribing by Dermatologists only
In line with PCMAS or specialist recommendation
In line with other garments
In line with PCMAS or specialist recommendation
Priorities Forum Lavender Statement
In line with Priorities Forum guidance
In line with NICE TAG 175 and TA 192
Specialist prescribing only
No clear evidence for using the MR formulation over the immediate release preparation
Priorities Forum Lavender Statement 43b
In line with agreed MOBB policy, products other than bread and flour are not recommended for
prescribing. LS 42c
Not prescribed on the NHS as defined by DoH
Hypersalivation - limited to children and young adults with neurodevelopmental disabilities who
have failed on standard treatment.
Insufficient evidence
Limited evidence
No clinical advantage
Moderate evidence
No good evidence to support use
Shared Care Protocol
Specialist prescribing only in line with local commissioning arrangements and TA 220, TA 225 & TA
233
Shared Care Protocol
In line with OUH guidance: Surgical antiemetic policy, Cancer antiemetic policy
Low priority
Shared Care Protocol NICE TA188
Shared Care Protocol
Shared Care Protocol
For anal fissure. Consider after lifestyle advice/use of topical anaesthetic prior to specialist referral
lack of evidence ofcost effectiveness
lack of evidence ofcost effectiveness
In line with lavender statement 6e
Not recommended
Lack of good quality evidence comparing emollients. Policy statement 88 recommends that
medicines that can be bought over the counter should be considered a low priority for prescribing
Shared Care Protocol
For limited use within OUH (NOC) as per agreed internal guidelines
Not included on OUH formulary. No evidence of improved compliance
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
iAluRil May 2014
IBANDRONATE APCO May 07
IBANDRONIC ACID (oral) for the prevention of skeletal events in metastatic and advanced breast cancer APCO
Sept 14
ICAPS® for age related muscular degeneration APCO July 04
IDARUBICIN HYDROCHLORIDE APCO july 2008
IFOSFAMIDE APCO Jul 08
IMATINIB APCO jul 04
IMATINIB HIGH DOSE for CML resistant to standard dose imatinib APCO Mar 12
IMIQUIMOD 3.75% CREAM for actinic keratosis APCO May 07
IMIQUIMOD 5% CREAM for recalcitrant anogenital warts APCO Aug 07
Immediate release FENTANYL intranasal spray for break through cancer pain APCO Mar 11
IMMUNOGLOBULINS: intravenous and subcutaneous APCO Mar 06
INDINAVIR APCO Sept 05
INFERTILITY TREATMENT
INFLIXIMAB APCO May 08
INOSINE PRABONEX
INOSITOL NICOTINATE APCO July 11
INSULIN DEGLUDEC APCO July 13
INSULIN DETEMIR APCO May 06
INSULIN GLARGINE
INTANZA® APCO July 11
IRINOTECAN HYDROCHLORIDE APCO Jul 08
ISONIAZID
ISOTRETINOIN – ORAL
IVABRADINE – arrhythmia APCO Jan 08
IVABRADINE - Heart Failure APCO Jan 13
IVABRADINE- Chronic stable angina APCO Mar 13
KALCIPOS-D® APCO Sep 11
KETAMINE APCO Mar 12
LACOSAMIDE APCO May 12
LACTASE DROPS (COLIEF ®) APCO Mar 10
LACTOSE FREE MILK APCO Mar 12
LACTOSE FREE MILK for colic
LAMIVUDINE for Hepatitis B APCO July 11
LAMIVUDINE for HIV
LANREOTIDE for acromegaly APCO Nov 11
LANREOTIDE for neuroendocrine tumours APCO Jan 12
LANTHANUM APCO May 07
Lapatinib in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptorpositive breast cancer that over expresses HER2 APCO July 12
LEFLUNOMIDE for inflammatory arthritis APCO May 11
LEFLUNOMIDE in children and adolescents (Rhematology) APCO July 11
LENALIDOMIDE APCO jul 2008
LETROZOLE APCO May 2007
LEUPRORELIN for Central Precocious puberty (CPP) APCO May 11
LIDOCAINE PLASTER for neuropathic pain
LINACLOTIDE for IBS (constipation predominent) APCO Mar 13
Black
Black
Yellow
Black
Red
Red
Red
Black
Black
Red
Black
Red
Red
Red
Red
Black
Black
Yellow cont
Brown
Brown
Black
Red
Red
Red
Yellow
Yellow SCP
Yellow SCP
Black
Yellow
Yellow
Black
Black
Black
Red
Red
Yellow SCP
Yellow SCP
Yellow
Continuation
Black
Yellow (NPT)
Yellow (NPT)
Red
Yellow
Continuation
Yellow
Yellow
Continuation
Black
specialist treatment - not on OUHT formulary
Not recommended
For patients that cannot tolerate injections
NICE Technology Appraisal 155 (May 2012) Macular degeneration (age-related) – ranibizumab
and pegaptanib
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Specialist prescribing only
For prescribing by secondary care oncologists/haematologists only. In line with NICE TA196 TA
209
In line with TA 241
Insufficient evidence of advantage over other treatment options or cost efficacy
For specialist GUM consultant prescribing only
unclear as to where this product should be used within the pathway, prescribing responsibilities
and which patient groups it would be appropriate for use in.
All should be provided through the OUHT
All HIV drugs should be prescribed by specialist centres only
In line with Priorities Forum Statement
Specialist prescribing only in line with local commissioning arrangements NICE TAG 187, TA195 &
TA199
Not recommended. Not on OUH formulary
in line with NICE TA223
In line with local guidelines, for intractable hypos & repeated DKA admissions only
Prescribe in line with national and local guidance
Restricted prescribing in accordance with Lavender Statement
Lack of evidence of improved efficacy compared to standard therapy
Specialist prescribing only
Specialist prescribing only
In line with BNF advice
Usually specialist prescribing only but may be appropriate for shared care where an individual,
patient specific protocol is agreed.
In line with SCP and NICE TA267
In line with SCP
The amount of calcium is less than the usual recommended intake. More cost effective
preparations available
Restricted prescribing for palliative care only, in line with the agreed shared care protocol
In line with the APCO approved shared care protocol
In line with lactose free milk policy and colic treatment pathway. Lack of evidence for
effectiveness.
Not recommended for babies without proven intolerance
Not recommended in line with lactose free milk policy
Shared Care protocol withdrawn - hospital prescribing only
All HIV drugs should be prescribed by specialist centres only
Shared Care Protocol
Only in line with Shared Care Protocol
Second line a Shared Care Protocol is available
In line with NICE TA 257
Shared Care Protocol
Shared Care Protocol
In line with NPSA Rapid Alert on Oral Anticancer Medicines
In line with local guidance.
Shared Care Protocol
Prescribe following recommendation from pain specialists only
Lack of evidence of efficacy compared with current treatments
LINAGLIPTAN APCO Mar 13
LINEZOLID APCO Jan 05
LIRAGLUTIDE 1.2mg (VICTOZA®) for the treatment of Type 2 diabetes mellitus APCO Jan 11
LIRAGLUTIDE 1.8mg (VICTOZA®) for the treatment of Type 2 diabetes mellitus APCO Jan 11
LISDEXAMFETAMINE DIMESYLATE (ELVANSE®) APCO July 13
LITHIUM
LIXISENATIDE APCO July 13
LOMITAPIDE for homozygous, familial hypercholesterolaemia May 2014
LOMUSTINE APCO Jul 2008
LOPINAVIR APCO sept 2005
LOXAPINE inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and
bipolar disorder APCO July 13
LUBIPROSTONE APCO Sept 2014
LURASIDONE APCO March 2015
MACUSHIELD® (vitamin prep) APCO Jan 11
MAGNESIUM ASPARTATE APCO March 2015
MANNITOL DRY POWDER for inhalation for the treatment of cystic fibrosis APCO Jan 13
MARAVIROC
MELATONIN (CIRCADIN®) for jet lag or primary insomnia APCO July 08
MELATONIN (Oxford Health-Mental Health) APCO Jan 12
MELATONIN for circadian rhythm sleep disorder APCO Jan 12
MELATONIN for sleep EEG APCO Jan 12
MELATONIN paediatric neurology use APCO May 05
MELPHALAN APCO July 2008
MEMANTINE for the treatement of Alzheimers discease APCO Sep 11
MEPITEL, MEPILEX & MEPITAC APCO Jul 06
MERCAPTOPURINE for inflammatory bowel disease APCO May 11
MESNA APCO Jul 2008
METHADONE ampoules APCO July 11
METHADONE CONCENTRATE (10mg, 20mg, 50mg/ml) APCO July 11
METHADONE solution 1mg/ml APCO July 11
METHADONE tablets 5mg APCO July 11
METHOTREXATE (oral) in children and adolescents (Rheumatology) APCO July 11
METHOTREXATE 10MG TABLETS
METHOTREXATE for dermatology APCO May 11
METHOTREXATE for inflammatory bowel disease APCO May 11
METHOTREXATE for inflammatory eye conditions APCO May 11
METHOTREXATE for neurology APCO May 11
METHOTREXATE for sarcoidosis APCO July 11
METHOTREXATE ORAL for paediatric gastroenterology APCO Mar 09
METHOTREXATE SUBCUTANEOUS (EBETREX®) APCO Sep 11
METHOTREXATE SUBCUTANEOUS for inflammatory arthritis APCO May 11
METHOTREXATE SUBCUTANEOUS For paediatric rheumatology APCO Sep 11
METHOTREXATE TABLETS for inflammatory arthritis APCO May 11
METHYLNALTREXONE APCO Sep 08
METHYLPHENIDATE APCO July 11
MIDAZOLAM BUCCAL (BUCCOLAM and EPISTATUS® - Unlicensed) APCO Sep 11
Brown
Red
Yellow
Black
Red
Yellow
Brown
Black
Red
Red
Black
In line with NICE TA 286
In line with NICE TA 318
Psychiatrists use only
Low priority for prescribing
Continuation after initiation by gastroenterologists
In line with NICE TA 266. Unclear whether this will be the responsibility of the National
Commissioning Board or CCGs from April 2013.
Specialist prescribing only
Not recommended
Brown
Red
Black
Yellow
Red
Red
Black
Red
Black
Red
Yellow
Red
Yellow
Red
Yellow
Red
Black
Black
Brown
Black
Yellow
Red
Yellow
Yellow
Yellow
Yellow
Yellow
Red
(NPT)
(NPT)
(NPT)
(NPT)
(NPT)
(NPT)
(NPT)
Black
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Black
Yellow
Yellow
Continuation
Red
MIDAZOLAM INTRA-NASAL APCO Mar 11
MIDODRINE APCO May 05
Mirabegron APCO jul 13
For use in patients with renal impairment in line with local Guidelines and NICE CG 87
Secondary care prescribing only
In line with APCO Liraglutide Guidance
In line with NICE TA203
Secondary care prescribing only
In line with Shared Care Protocol
In line with local GLP1 guidelines
specialised commissioning/not routinely commissioned
In line with NPSA Rapid Alert on Oral Anticancer Medicines
All HIV drugs should be prescribed by specialist centres only
Red
Yellow
Specialist prescribing within Oxford Health Mental Health - for child and adolescent prescribing only
Not recommended
Secondary care prescribing only
An individual Shared Care Protocol will be issued each time melatonin is recommended for children
under the care of paediatric neurology depending on the indication
In line with NPSA Rapid Alert on Oral Anticancer Medicines
In line with PCMAS or specialist recommendation
In line with local Wound Management Guidance
Shared Care Protocol
Secondary care prescribing only
In line with National Clinical Assessment Service (NCAS guidance)
In line with APCO approved Guidance for Substance Misuse
Under shared care drug misuse LES only
In line with APCO approved Guidance for Substance Misuse
Shared Care Protocol
Secondary care prescribing only
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Secondary care prescribing only
Metoject® is the brand of choice for Oxfordshire – restricted to one brand across the health
economy
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Not appropriate for prescribing
To be used following recommendations from Oxford Health (Mental Health) consultants only. A
Shared Care Protocol is available
Shared Care Protocol
For use by the Oxfordshire Salaried Primary Care Dental Service only for special care adults and
adults with needle phobia - subject to the medico-legal aspects being agreed with Oxford Health.
Secondary care prescribing only
In line with OAB guidelines
MITOBRONITOL APCO jul 08
MITOMYCIN APCO jul 08
MITOTANE APCO sept 05
MITOXANTRONE APCO jul 08
MODAFINIL
MODAFINIL for excessive daytime sleepiness in myotopic dystrophy May 2014
MOLLUDAB APCO Sept 14
MOVICOL APCO Jan 05
MYCOPHENOLATE for rheumatology APCO Nov 10
MYCOPHENOLATE in Autoimmune Liver Disease and Liver Transplant APCO Jan 12
MYCOPHENOLATE in dermatology APCO Sep 11
MYCOPHENOLATE in Inflammatory Bowel Disease APCO Jan 12
MYCOPHENOLATE in Interstitial Lung Disease APCO Nov 11
MYCOPHENOLATE in renal transplant APCO Sept 05
NALMEFENE APCO Nov 14
NALOXEGOL for treating opioid induced constipation APCO Sept 15
NALTREXONE APCO Nov 04
NALTREXONE low dose for multiple sclerosis APCO Mar 05
NANO-PARTICLE BOUND PACLITAXEL for metastatic breast cancer APCO sept 2010
NAPROXEN & ESOMEPRAZOLE (VIMOVO®) APCO Jan 12
NATALIZUMAB for treatment of MS APCO sept 2012
NEGATIVE PRESSURE WOUND THERAPY
NELARABINE APCO Jul 08
NELFINAVIR APCO Sept 2005
NEVIRAPINE APCO Sept 2005
NICOTINAMIDE for Bullous Pemphigoid APCO Jan 14
NICOTINE REPLACEMENT THERAPY
NILOTINIB for CML resistant to standard dose imatinib APCO Jun 2007
NINTEDANIB for previously treated, locally advanced, metastatic or locally recurrent non-small-cell lung cancer
APCO Sept 15
NUTRITIONAL SUPPLEMENTS (oral) for patients in care and nursing homes Sept 15
NUTRITIONAL SUPPLEMENTS – dessert style supplements (eg FORTICREME, FRESUBIN CREME)
NUTRITIONAL SUPPLEMENTS 1kcal/ml (eg ENSURE®, FRESUBIN®) APCO Jan 11
NUTRITIONAL SUPPLEMENTS 2kcal/ml (eg TWOCAL®, ENSURE TWOCAL®)
NUVARING APCO July 09
OBINUTUZUMAB in combination with chlorambucil for untreated chronic lymphocytic leukaemia APCO July 15
OCRIPLASMIN for treating vitreomacular traction APCO Nov 13
OCTREOTIDE for acromegaly APCO Nov 11
OCTREOTIDE for neuroendocrine tumours
OCUVITE for age related muscular degeneration APCO july 04
OFATUMUMAB for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
APCO Nov 10
OFATUMUMAB in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
APCO July 15
OLANZAPINE for Behavioural and Psychiatric symptoms of dementia APCO Sep 11
OLANZAPINE IM APCO May 04
OMALIZUMAB for previously treated chronic spontaneous urticaria APCO July 15
OMALIZUMAB in asthma for adults and children over 12
Red
Red
Red
Red
Yellow
Continuation
Red
Black
Brown
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Red
Red
Brown
Yellow
Continuation
Black
Black
Black
Red
Yellow
Red
Red
Red
Black
Brown
Red
Red
Black
Brown
Black
Brown
Brown
Red
Red
Yellow
Red
Black
Black
Red
Brown
Red
Red
Red
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Specialist prescribing only
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Specialist prescribing only
Prescribe only following recommendation from local specialist in sleep disorders
In line with EMA safety guidance
Limited evidence, can be purchased
Should only be second/third line for patients who cannot tolerate lactulose/fybogel
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Shared Care Protocol
Renal transplant drug for specialist initiation and prescribing only
Refer patients to Public Health Drug and Alcohol Service
for patients who have not responded to other treatments in line with NICE TA 345
May be initiated by a consultant hepatologist for cholestatic itching
Unlicensed with little supporting evidence – should not be prescribed
Specialised commissioning decision
No studies comparing with standard treatment. Esomeprazole 20mg is also classified locally as
black.
In line with NICE TA 127
Guidelines
Specialist prescribing only
All HIV drugs should be prescribed by specialist centres only
All HIV drugs should be prescribed by specialist centres only
Unlicesnsed - lack of evidence
Priorities Forum Lavender Statement
In line with TA 241
In line with NICE TA 347
NOT PEG TUBE PATIENTS. Food fortification by care home staff should be used in most cases.
Exceptions are patients with head and neck cancer or motor neurone disease
Restricted for use only where recommended by a dietitan / Speech & Language therapist in
dysphagia. In line with local Guidelines for the Management of Undernutrition.
Use 1.5kcal/ml supplements (such as Complan Shake) where a nutritional supplement is
appropriate to prescribe. In line with local Guidelines for the Management of Undernutrition.
Restricted for use only where a patient is under a specialist/dietitian. 2kcal/ml supplements can be
used to reduce the volume in bolus feeding via PEG tube or in fluid restricted patients, such as
ascites in liver disease. In line with local Guidelines f
2nd or 3rd line option in line with specific patient criteria.
in line with NICE TA 343
In line with NICE guidance
Only in line with Shared Care Protocol
Specialised Commissioning only
Low priority for prescribing
In line with NICE TA202
In line with NICE TA 344
Short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of
Dementia: Prescribing Guidance (2nd line IF antipsychotic required - off license use)
Oxford Health (Mental Health) specialists only
in line with NICE TA 339
Specialist prescribing only in line with NICE TA133
OMALIZUMAB for the treatment of severe persistant allergic asthma in children aged 6-11 APCO Nov 2010
OMEGA 3 SUPPLEMENTS for hypertriglyceridaemia APCO Mar 11
ONDANSETRON APCO May 10
ORLISTAT
OSELTAMIVIR – for the treatment or prophylaxis of influenza
OXALIPLATIN APCO Jul 08
OXCODONE 50mg/5mL APCO May 11
OXYBUTYNIN PATCH APCO May 11
OXYCODONE APCO may 11
OXYCODONE and NALOXONE (TARGINACT®) APCO Jul 09
PABRINEX® APCO Nov 11
PACLITAXEL APCO Jul 08
PALIFERMIN APCO July 08
PALIPERIDONE APCO sept 07
PALIVIZUMAB APCO Nov 10
PANITUMUMAB APCO July 08
PANITUMUMAB for metastatic colorectal cancer after first line chemotherapy APCO Mar 12
PANITUMUMAB in combination with chemotherapy for treatment of metastatic colorectal cancer APCO Jan 12
PARACETAMOL INJECTION APCO Jan 06
PARACHLOROPHEYLOLANINE APCO Jul 08
PARATHYROID hormone for men with primary and secondary prevention of fractures APCO Nov 12
PAZOPANIB for the first line treatment of metastatic renal cell carcinoma APCO May 11
PEG INTERFERON APCO July 05
PEGAPTANIB
PEGAPTANIB for diabetic macular oedema APCO Jan 12
PEGINTERFron alfa and ribavirin (VIRAFERONPEG®) for the treatment of chronic hepatitis C (part review of
TAGs 75 and 106) APCO Nov 10
PEGLOTICASE for treating severe debilitating chronic tophaceous gout APCO July 13
PEGVISOMANT APCO Sep 05
PEMETREXED APCO jul 2008
PENICILLAMINE APCO Nov 10
PENTOSTATIN APCO jul 08
PENTOXIFYLLINE APCO July 11
PENTOXIFYLLINE for gastric/liver indications APCO Jan 14
PENTOXIFYLLINE for venous leg ulcer APCO Nov 13
PENTOXIFYLLINE in osteoradionecrosis (ORN) of the jaws APCO Nov 12
PERAMPANEL APCO Nov 13
PERHEXILINE APCO Nov 13
PERINDOPRIL ARGININE PLUS INDAPAMIDE (COVERSYL®) APCO July 09
PHARMALGEN APCO Mar 12
PIMECROLIMUS cream APCO Jul 11
PIRFENIDONE for treating idiopathic pulmonay fibrosis APCO May 13
PLERIXAFOR for Mutiple myeloma
PLERIXAFOR for non-Hodgkin lymphoma
PORFIMER SODIUM
POSACONAZOLE APCO Nov 06
PRAMIPEXOLE for Idiopathic Restless Leg Syndrome APCO Sep 11
PRASUGREL APCO May 10
PREDNISOLONE 0.01%,0.03% & 0.1% EYE DROPS APCO Jan 04
PREDNISOLONE 0.03% & 0.3% PRESERVATIVE FREE EYE DROPS APCO Jan 04
PREDNISOLONE EC tabs APCO Jan 11
PREGABALIN for neuropathic pain
PRISTINAMYCIN APCO Nov 06
Black
Black
Yellow
Brown
Brown
Red
Brown
Brown
Brown
Black
Yellow
Red
Red
Black
Red
Red
Black
Black
Red
Red
Black
Red
Red
Black
Black
Red
Black
Black
Red
Yellow (NPT)
Red
Black
Red
Yellow
Yellow
Yellow
Shared Care
Red
Black
Red
Yellow
Red
Black
Red
Red
Red
Yellow
Yellow
Red
Red
Black
Yellow
Continuation
Red
In line with NICE TA201
In line with NICE CG172
In line with OUH guidance: Surgical antiemetic policy, Cancer antiemetic policy
Only prescribe following NICE CG43
Only prescribe according to guidelines
Specialist prescribing only
Restricted use – within syringe drivers where volume is an issue
In line with Prescribing guidance, for patients with swallowing difficulties
In line with Opoid Guidelines
Lack of evidence of cost-effectiveness
In line with Guidance for Primary Care Alcohol Detoxification
Specialist prescribing only
Specialist prescribing only
APCO September 2007
Specialist prescribing only
Specialist prescribing only
In line with NICE TA 242
In line with NICE TA 240
Used selectively in OUHT
Specialist prescribing only
in Line with lavender statement 232
In line with TA 215
Secondary care prescribing only
Not recommended in line with NICE TA155
NICE TA 274
In line with NICE TA200
In line with NICE TA 291
Considered low priority for prescribing
In line with NPSA Rapid Alert on Oral Anticancer Medicines NICE TAG 190
Shared Care Protocol
Specialist prescribing only
in line with NICE TA223
Specialist use only
In line with Shared Care Protocol
In line with SCP
In line with Shared Care Protocol
Unlicensed
In line with OUH MAC decision
In line with NICE TA 246
For moderate atopic eczema on the face and neck of children aged 2-16yrs in line with NICE TA
82
In line with NICE TA 282
Specialised commissioning decision
Specialist prescribing only
Specialist prescribing only
Specialist prescribing only
Shared Care Protocol
In line with NICE TA 182 – patient should be stabilised by OUH and length of treatment should be
advised when primary care is requested to take over prescribing.
All specially prepared eye drops to be prescribed and dispensed by the OUHT
All specially prepared eye drops to be prescribed and dispensed by the OUHT
Lack of evidence of cost-efficacy
Prescribe following recommendation from pain specialists only
Specialist prescribing only
PRO-BIOTICS
PROCARBAZINE HYDROCHLORIDE
PROFLAVINE CREAM APCO Sep 13
PROPIVERINE APCO May 11
PRUCALOPRIDE for chronic constipation in women APCO May 12
PYRAZINAMIDE
QLAIRA® phased combined hormonal contraceptive APCO July 11
QUETIAPINE for Behavioural and Psychiatric symptoms of dementia APCO July 13
QUETIAPINE for GAD APCO July 13
QUETIAPINE XL APCO Sep 09
RACECODATRIL for children and adults APCO Mar 13
RALTEGRAVIR
RALTITREXED
RAMELTEON APCO May 08
RANIBIZUMAB for choroidal neovascularisation associated with a pathological myopia
RANIBIZUMAB for diabetic macular oedema APCO Mar 13
RANIBIZUMAB for macular oedema caused by retinal vein occlusion APCO Jan 12
RANIBIZUMAB for wet AMD
RANOLAZINE APCO July 12
RASAGILINE APCO Nov 13
RAZOXANE
RECOMBINANT HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR
RELVAR ELLIPTA for Asthma March 2014
RELVAR ELLIPTA for COPD May 2015
RELVAR ELLIPTA for non-compliant, poorly controlled teenage asthmatics at stage 5 of BTS May 2014
RESPERATE® APCO Mar 12
RETAPAMULIN OINTMENT APCO May 08
RETIGABINE for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without
secondary generalisation APCO Sep 11
RETIN-A for stretch marks
RIFAMPICIN APCO May 12
RIFAMPICIN for TB APCO July 09
RIFAXIMIN for hepatic encephalopathy APCO May 15
RILUZOLE APCO May 13
RISPERIDONE for Behavioural and Psychiatric symptoms of dementia APCO Sep 11
RISPERIDONE IM APCO July 05
RITONAVIR
RITUXIMAB
RITUXIMAB for mantle cell lymphoma
RIVAROXABAN for the prevention of stroke and systemic embolism in people with atrial fibrillation. APCO Sep 12
RIVAROXABAN for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and
pulmonary embolism(TA261) APCO May 13
RIVAROXABAN for preventing adverse outcomes of acute coronary system
RIVASTIGMINE (EXELON®) PATCH APCO Sep 09
RIVASTIGMINE for the treatment of Alzheimers Disease APCO Sep 11
RIVASTIGMINE for the treatment of dementia associated with Parkinson’s disease or Lewy Bodies
ROFECOXIB INJECTION
ROFLUMILAST APCO Sep 12
Black
Red
Black
Black
Brown
Red
Black
Brown
Black
Red
Black
Red
Red
Black
Red
Red
Red
Red
Yellow
Yellow
Red
Red
Black
Yellow
Yellow
continuation
Black
Black
Yellow
Continuation
Black
Brown
Red
Red
Yellow
Brown
Red
Red
Red
Black
Brown
Yellow
Yellow
Yellow
Continuation
Yellow
Yellow
Continuation
Black
Black
In line with Priorities Forum Policy Statement 125
In line with NPSA Rapid Alert on Oral Anticancer Medicines
No evidence to support use
In line with local prescribing guidance
In line with TA 211
Specialist prescribing only
No evidence of clinical benefit over alternatives and more expensive, no long term safety data.
Short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of
Dementia: Prescribing Guidance (2nd line IF antipsychotic required - off license use)
Limited evidence suggests no greater efficacy than antidepressants
No clinical evidence of increased tolerability compared to immediate release therapy. Only
anecdotal evidence of benefit in titration.
Limited evidence
In line with Priorities Forum Lavender Statement
Specialist prescribing only
Currently unlicensed - No Prescribing
In line with NICE ta 298
In line with NICE TA 274
In line with NICE TA 283
In line with NICE TA 155
Shared Care Protocol
Parkinson's treatment for specialist initiation, second line after selegiline.
Specialist prescribing only
Specialist prescribing only
Safety concerns and lack of robust evidence
2nd line option if steroid inhaler indicated In line with local COPD guidelines
for non-compliant, poorly controlled teenage asthmatics at stage 5 of BTS on recommendation
from paediatric respiratory only
Routine provision of relaxation therapies by primary care teams is not currently recommended
within NICE CG 127 Hypertension
Not recommended
In line with NICE TA 232
Not recommended in line with Priorities Forum statement 6
Restricted prescribing in line with antimicrobial guidance
Specialist prescribing only
In line with NICE TA 337
In line with NICE TA20 and Shared Care Protocol
Short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of
Dementia: Prescribing Guidance (1st line IF antipsychotic required)
Secondary care prescribing only
All HIV drugs should be prescribed by specialist centres only
Specialist prescribing only in line with local commissioning arrangements and TA 193, TA195,
TA226 & TA243
In line with Policy Statement 207/MOBBB Statement 54
In line with NICE TA 256 and local guidance
In line with NICE TA 261. First three months tx to be provided by OUH for new DVT/PE.
In line with NICE TA 335
Only if patient unable to tolerate oral therapy, clinical evidence not sufficient to recommend first
line.
Shared Care Protocol and in-line with TA 217
In line with Priorities Forum Statement 134
Not on OUHT formulary for acute pain due to lack of evidence
In line with NICE TA 244 - recommended only as part of a clinical trial
ROMIPLOSTIM for the treatment of chronic immune or idiopathic thrombocytopenic purpura APCO May 11
ROPINIROLE for restless legs - mild to moderate
ROPINIROLE for restless legs – severe & persistent
Red
Black
Red
In line with TA 221
In line with Priorities Forum July 2008
Specialist prescribing only in line with Priorities forum July 2008
Brown
For use only where other first and second line statins have not been tolerated, or for very high risk
secondary prevention patients where first and second line agent have not been effective.
Following specialist diagnosis in line with the recommendations for the management of Parkinson
disease in NICE Clinical Guideline 35 and
• In patients unable to tolerate ropinirole or
• In patient with an insufficient response to ropinerole or
• In patient unable to swallow oral medicines
Specialist only in Lennox Gastaut Syndrome
In line with NICE TA 289
All HIV drugs should be prescribed by specialist centres only
Effect size of reducing spasticity is small, with very little translation into patient benefit. No cost
effectiveness studies. Few long term cannabinoids studies.
For use in line with In line with NICE Type 2 Diabetes CG87. Alogliptin is first choice DPP4 APCO
May 14
In line with NICE TA 350
Shared Care Protocol Jan 12
Specialist prescribing only
In line with lavender statement 233
For use in line with In line with NICE Type 2 Diabetes CG87. Alogliptin is first choice DPP4 APCO
May 14
Only for treatment of hypercalcaemia anociated skeletal metastases in patients with breast cancer
or multiple myeloma following recommendation from specialists
ROSUVASTATIN APCO March 2011
Brown
ROTIGOTINE PATCH for parkinsons disease or restless legs APCO Mar 11
RUFINAMIDE APCO Sep 08
RUXOLITINIB for disease-related splenomegaly or symptoms in adults with myelofibrosis APCO Jul 13
SAQUINAVIR APCO Nov 06 appendix B
SATIVEX® APCO Nov 10
SAXAGLIPTIN APCO Nov 10
SECUKINUMAB for treating moderate to severe plaque psoriasis APCO Sept 15
SEVELAMER APCO Aug 07
SILDENAFIL for pulmonary artery hypertension APCO Mar 11
SILDENAFILfor penile rehabilitation after radical prostatectomy Priorities Committee Sep 12
SITAGLIPTIN (JANUVIA®) APCO Jul 11
SODIUM CLODRONATE APCO Nov 06
SODIUM OXYBATE
SOLIFENACIN 5mg
SOLIFENACIN 10MG
SOLIFENACIN and TAMSULOSIN combination APCO Sept 2014
SOMATROPIN for the treatment of growth failure in children APCO Jul 10
SORAFENIB (first- and second-line) for the treatment of advanced and/or metastatic renal cell carcinoma APCO
Sep 09
SORAFENIB for the treatment of advanced hepatocellular carcinoma APCO Jul 10
SOUVENAID ® APCO Jan 13
STAVUDINE APCO Nov 06 appendix B
STIRIPENTOL APCO Nov 14
Red
Black
Red
Black
Brown
Red
Yellow
Red
Black
Brown
Yellow
Continuation
Red
Yellow
continuation
Yellow
continuation
Black
Yellow
Black
Black
Black
Red
Red
Black
STOMA products APCO July 11
STRIVERDI RESPIMAT Nov 14
STRONTIUM
STRONTIUM for men with primary and scondary prevention of fractures APCO Nov 12
SULPHAMETHOXYPYRIDAZINE for pemphigoid May 2014
SULPHASALAZINE for inflammatory arthritis APCO Nov 10
SULPIRIDE for Behavioural and Psychiatric symptoms of dementia APCO May 11
SUMATRIPTAN RADIS
SUNITINIB
SUNITINIB for the treatment of gastrointestinal stromal tumours APCO Nov 09
SYLK® Paraben free personal lubricant APCO Jan11
TACROLIMUS for liver transplantation APCO Jul 11
TACROLIMUS for renal transplantation
TADALAFIL (for pulmonary artery hypertension)
Black
Brown
Black
Black
Yellow (NPT)
Brown
Black
Red
Red
Black
Yellow
Red
Red
In line with OAB guidelines
In line with OAB guidelines
Shared Care Protocol, Growth Hormone Paediatric
In line with NICE TA178
In line with NICE TA189
Some evidence of improved memory but limited to very early disease only and no improvement in
cognition demonstrated. Can be purchased OTC.
All HIV drugs should be prescribed by specialist centres only
Specialist prescribing only
certain Suportx, Cuiwear, Comfizz, Simplicity products considered to be cosmetic rather than
clinical. Refer to Stoma Prescribing Guidance and 'Stoma products' hyperlink on left for more
detail.
LABA only licensed in COPD, no advantage over existing treatment options
See MHRA safety alert
in Line with lavender statement 232
Hospital only drug - not on OUHT formulary
Shared Care Protocol
Short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of
Dementia: Prescribing Guidance (2nd line IF antipsychotic required - off license use)
Not recommended
Secondary care prescribing only for the first line treatment of advanced and/or metastatic renal
cell carcinoma
In line with NICE TA179
Not recommended for prescribing, available for OTC purchase
Shared Care Protocol
Specialist initiation and prescribing only
Specialist prescribing only
TADALAFIL for penile rehabilitation pre- and post- radical prostatectomy May 2014
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia APCO Mar 13
TADALAFIL ONCE A DAY (CIALIS®) APCO Mar 09
TALAPREVIR for the treatment of genotype 1 chronic hepatitis C APCO May 12
TAMSULOSIN MR (FLOMAXTRA-XL®) APCO Sep 11
TAPENTADOL APCO July 11
TARGINACT apco Jul 09
TEGAFUR APCO Jul 08
TEICOPLANIN APCO Jan 05
TELBIVUDINE
TEMOPORFIN
TEMOZOLOMIDE - dose-dense in recurrent glioblastoma multiforme
TEMOZOLOMIDE for malignant glioma
TEMSIROLIMUS (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
TEMSIROLIMUS for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) APCO
Nov10
TENOFOVIR APCO Sept 05
TENOFOVIR DISOPROXIL for chronic hepatitis B APCO Sept 09
TERBINAFINE
TERIPARATIDE APCO May 12
TERIPARATIDE for men with primary and scondary prevention of fractures APCO Nov 12
TESTOSTERONE (ANDROPATCH®) PATCH APCO Aug 07
TESTOSTERONE (INTRINSA®) PATCH for hypoactive sexual disorder APCO June 07
TESTOSTERONE (STRIANT®) BUCCAL TABLETS APCO Aug 07
TESTOSTERONE GEL (TESTIM® & TESTOGEL®) APCO Jan 10
TESTOSTERONE GEL (TOSTRAN®) APCO Jan 09
TESTOSTERONE UNDECANOATE (NEBIDO®) APCO Nov 11
THALIDOMIDE and Bortezomib for the first-line treatment of multiple myeloma
THICKENERS for dysphasia APCO Sept 06
THIOTEPA APCO Jul 08
TICAGRELOR for patients with ACS APCO Nov 12
TINZAPARIN APCO Jan 14
TINZAPARIN APCO Sep 08
TIOGUANINE Jul 08 NPSA alert
TIOTROPIUM for ASTHMA March 2015
TIOTROPIUM RESPIMAT APCO Jul 08
TOBRAMYCIN (INHALED) (TOBI PODHALER®) APCO Nov11
TOBRAMYCIN (INHALED) (TOBI® & BRAMITOP®) APCO Jan 11
TOCILIZUMAB for rheumatoid arthritis APCO Mar 12
TOCILIZUMAB for the treatment of juvenile idiopathic arthritis APCO Jan12
TOLCAPONE APCO Jul 06
TOLTERODINE APCO May 11
TOLTERODINE MR APCO May11
TOPICAL steroid for Wound Management APCO Mar 13
TOPOTECAN APCO Jan10
TRABECTEDIN APCO Mar10
TRABECTEDIN for the treatment of relapsed ovarian cancer APCO May 11
TRAMACET APCO Mar06
TRASTUZUMAB APCO Jan11
TRASTUZUMAB in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone
receptor- positive breast cancer that over expresses HER2 APCO Jul12
TREDAPTIVE for hypertryglyceridaemia APCO Mar 11
Black
Black
Black
Red
Black
Black
Black
Red
Red
Black
Red
Red
Red
Black
Black
Red
Red
Brown
Yellow
Black
Black
Black
Black
Yellow (NPT)
Yellow (NPT)
Yellow (NPT)
Red
Yellow
Continuation
Red
Yellow
Continuation
Yellow shared
care
Black
Red
Yellow
Brown
Black
Yellow
Red
Red
Black
Brown
Black
Brown
Red
Red
Black
Black
Red
Black
Black
In line with lavender statement 233
NICE appraisal terminated
Not recommended
In line with NICE TA252
No evidence of clinical advantage over standard preparation
Lack of evidence of clinical efficacy compared to standard treatment
lack of evidence of cost effectiveness
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Secondary care prescribing only
In line with NICE TA154
Specialist prescribing only
Specialist prescribing only
Specialist prescribing only
In line with NICE TA 178
In line with NICE TA207
All HIV drugs should be prescribed by specialist centres only
In line with NICE TA 173
Follow recommendations from Priorities Forum Lavender Statement.
Shared Care Protocol
in Line with lavender statement 232
Not recommended for use as no more clinically effective than testogel, testim and sustanon but
more expensive
For hypoactive sexual disorder in the general female population (out of license use)
Not recommended for use as no more clinically effective than testogel, testim and sustanon but
more expensive
Prescribe for males only within licensed indications according to shared care protocols
Prescribe for males only within licensed indications according to shared care protocols
Prescribe for males only within licensed indications according to shared care protocols
In line with TA 228
Only on recommendation of Speech and Language Therapy
Specialist prescribing only
on recommendation from cardiologists only, in line with agreed guidelines
For SE locality patients referred to RBH ONLY
Not appropriate for prescribing
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Specialist initiation add on to LABA and corticosteroids
Restricted for patients unable to use Handihaler
No request to include on OUH formulary
Shared Care Protocol
In line with TA 247
In line with NICE TA 238
Not recommended. Awaiting consideration by OUHT MAC
See OAB guidelines
see OAB guidelines
In line with agreed local guidelines
Specialist prescribing only. NICE TA 184 gives guidance for the treatment of relapsed small-cell
lung cancer
Specialist prescribing only in line with NICE TA185.
In line with TA 222
Not recommended for prescribing due to sub-therapeutic doses
Specialist prescribing only. TA 208
In line with NICE TA 257
Withdrawn from market
TREOSULFAN APCO Jul 08
TRETINOIN IV
TRIADCORTYL APCO Jan 14
TRICLOFLOS APCO May 04
TRIMOVATE for wound management APCO Nov 13
TRIPTORELIN (DECAPEPTYL SR®) APCO Sep 11
TRIPTORELIN for central precocious puberty APCO Sept 05
TROPISETRON APCO May 10
TROSPIUM APCO Jan 14
ULIPRISTAL ACETATE (ELLAONE®) APCO Nov 09
ULIPRISTAL ACETATE (ESMYA®) APCO July 15
USTEKINUMAB for the treatment of adults with moderate to severe psoriasis APCO Nov09
USTEKINUMAB for treating psoriatic arthritis APCO Jul14
VACUUM ERECTION DEVICES for penile rehabilitation after radical prostatectomy APCO Nov 12
VARENICLINE (CHAMPIX®) APCO Sept07
VEDOLIZUMAB for treating moderately to severely active ulcerative colitis APCO July 14
VENLAFAXINE for Hot Flushes APCO Nov 05
Brown
Red
Black
Black
VENLAFAXINE MR CAPSULES APCO Sep 11
VIAGRA®
Black
Brown
VILDAGLIPTIN APCO July 11
VINBLASTINE SULPHATE APCO Jul08
VINCRISTINE SULPHATE APCO Jul08
VINDESINE SULPHATE APCO Jul 08
VINORELBINE APCO Jul 08
VIRULITE COLD SORE MACHINE APCO Mar 08
Red
Red
Red
Red
Black
VITAMIN PREPARATIONS for age related macular degeneration APCO May 07
VORICONAZOLE APCO July 03
YASMIN® APCO Jan 11
YES APCO Jul14
ZALCITABINE APCO Sept 05
ZANAMIVIR - for the TREATMENT or PROPHYLAXIS of influenza APCO Mar09
ZIDOVUDINE APCO Sept 05
ZOELY ® APCO May 13
ZOLEDRONIC ACID for men with primary and scondary prevention of fractures APCO Nov 12
ZOLEDRONIC ACID for Pagets, Osteoporosis and home TPN patients APCO Jun 07
ZOLEDRONIC ACID for steroid induced osteoporosis APCO Mar 10
ZONISAMIDE APCO Nov 10
ZUCLOPENTHIXOL ACETATE APCO May 2014
Drug
Jaydess 13.5 mg intrauterine delivery system
Red
Red
Red
Red
Yellow
Yellow
Yellow
Black
Brown
Brown
Black
Red
Black
Black
Black
Red
Brown
Black
Red
Brown
Red
Black
Black
Red
Brown
Yellow
Red
Traffic Light
Holding List
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Specialist prescribing only
Prescribed and dispensed by the OUHT
Specialist initiation for wound bed healing
In line with other analogues, 6 monthly administration and is cost neutral
Shared Care Protocol
In line with OUH guidance: Surgical antiemetic policy, Cancer antiemetic policy
In line with OAB guidelines
For women who present between 72 -105 hours and an IUD is not felt to be appropriate
For uterine fibroids - no request to use this from OUH gynae
In line with NICE TA 180
NICE TA313
In line with lavender statement 233
To be used second line following NRT or where intolerant to NRT - APCO approved local guidance
for patients intolerant of NRT or where NRT is unsuccessful.
in line with NICE TA 342
Not licensed. Awaiting a review of the evidence
No evidence for using MR capsules rather than tablets – the MR tablets have significant cost
savings benefits
Generic prescribing only APCO Sep 14
For use in line with In line with NICE Type 2 Diabetes Mellitus clinical guideline. Vildagliptan not
first choice DPP4 in line with local Guidelines.
Specialist prescribing only
Specialist prescribing only
Specialist prescribing only
In line with NPSA Rapid Alert on Oral Anticancer Medicines
Not recommended
Not recommended. Including Ocuvite Presser Vision, VisiVite Original Formula, Viteyes AREDS
Formula –
Specialist prescribing only
Restricted use for women who are unable to tolerate alternative COCs
Can be purchased OTC policy lavender statement 88
All HIV drugs should be prescribed by specialist centres only
Only prescribe according to guidelines NICE TA168
All HIV drugs should be prescribed by specialist centres only
No evidence of clinical benefit over alternatives and more expensive, no long term safety data.
in Line with lavender statement 232
Specialist prescribing only. In line with Secondary Prevention of Fragility Fractures Algorithm for
Treatment
In line with local steroid induced OP pathway
In line with shared care protocol.
to be used under the direction of consultant psychiatrist
Rationale
Awaiting Public Health review